CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...

Among patients who received four-drug consolidation therapy, 84% had measurable residual disease (MRD)-negative status before ...

Find insight on Roche, Bangkok Dusit Medical Services, ResMed and more in the latest Market Talks covering the health care ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

Multiple myeloma (MM) is an incurable haematological malignancy, but patient survival outcomes have been lately improved by ...

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

VersaBank (VBNK.T) is expected to report $0.27 for 2Q. Powered by Onclusive and Dow Jones. Advance Auto Parts Raised to Neutral From Sell by Redburn Atlantic ...

The candidate, named KT-621, is being positioned as a potential oral competitor to Sanofi and Regeneron's blockbuster ...

We are living in the era of cautious consumerism. These past weeks and months have been a trying time for investors, with the stock market roiled by President Donald Trump's tariff plans and a ...